From the Journals

Women’s Risk for Lupus Rises With Greater Intake of Ultraprocessed Foods


 

TOPLINE:

A higher intake of ultraprocessed foods increases the risk for systemic lupus erythematosus (SLE) by over 50% in women. The risk doubled in those with anti–double-stranded DNA antibodies.

METHODOLOGY:

  • Researchers assessed 204,175 women from two Nurses’ Health Study cohorts from 1984 to 2016.
  • Participants completed semiquantitative food frequency questionnaires every 4 years for the assessment of dietary intake.
  • Incident SLE cases were self-reported and confirmed using medical records, with 212 cases identified.

TAKEAWAY:

  • A higher cumulative average daily intake of ultraprocessed foods was associated with a 56% increased risk for SLE (95% confidence interval [CI], 1.04-2.32).
  • The risk for anti–double-stranded DNA antibody-positive SLE was more than doubled (hazard ratio, 2.05; 95% CI, 1.15-3.65).
  • Sugar or artificially sweetened beverages were associated with a 45% increased risk for SLE (95% CI, 1.01-2.09).
  • No significant interactions with body mass index were observed in the association between ultraprocessed food intake and SLE.

IN PRACTICE:

This study is too preliminary to have practical application.

SOURCE:

The study was led by Sinara Rossato, PhD, Harvard T.H. Chan School of Public Health, Boston. It was published online in Arthritis Care & Research.

LIMITATIONS:

The study’s generalizability is limited due to the predominantly White female population of registered nurses. The relatively high baseline age of participants may not fully capture the peak incidence age range for SLE. The observational nature of the study cannot establish causality between ultraprocessed food intake and SLE risk.

DISCLOSURES:

The study was supported by the National Institutes of Health. The authors did not declare any competing interests.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

Recommended Reading

The Appendix: Is It ’Useless,’ or a Safe House and Immune Training Ground?
MDedge Rheumatology
EULAR 2024 Preview: Therapeutics in Development Take Center Stage
MDedge Rheumatology
Upadacitinib Proves Successful in First JAK Inhibitor Trial for Giant Cell Arteritis
MDedge Rheumatology
Autoantibodies Nonspecific to Systemic Sclerosis May Play Role in ILD Prediction
MDedge Rheumatology
Sex-Related Differences Found in IgG4-Related Disease Epidemiology
MDedge Rheumatology
Low Hydroxychloroquine Levels in Early Pregnancy Tied to Greater Flares in SLE
MDedge Rheumatology
‘Therapeutic Continuums’ Guide Systemic Sclerosis Treatment in Updated EULAR Recommendations
MDedge Rheumatology
Form of B12 Deficiency Affecting the Central Nervous System May Be New Autoimmune Disease
MDedge Rheumatology
CAR T-Cell Treatment Data Expands in Refractory Rheumatic Diseases, Demonstrating Consistent Efficacy
MDedge Rheumatology
Sustained Low Lupus Disease Activity May Give Lower Risk for Flares, Organ Damage
MDedge Rheumatology